Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 13/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.65 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 4/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966150 | 0.94 | PDGFRB (0.70) | PDGFRBPDGFRAKITKDRFLT3 | |
| SCHEMBL4965795 | 0.91 | PDGFRB (0.66) | PDGFRBPDGFRAPDE10AKITKDR | |
| SCHEMBL4966363 | 0.89 | PDGFRA (0.56) | PDGFRBPDGFRAPDE10AHTR1AADRA1D | |
| SCHEMBL4966797 | 0.89 | PDE10A (0.56) | PDGFRBPDGFRAPDE10AKITKDR | |
| SCHEMBL4967916 | 0.89 | PDGFRA (0.57) | PDGFRBPDGFRAPDE10AHTR1AADRA1D | |
| SCHEMBL4970207 | 0.88 | PDGFRB (0.67) | PDGFRBPDGFRAKITKDRFLT3 | |
| SCHEMBL4966727 | 0.88 | PDGFRA (0.59) | PDGFRBPDGFRAKITKDRPDE3A | |
| SCHEMBL4970154 | 0.88 | PDGFRB (0.69) | PDGFRBPDGFRAKITKDRFLT3 | |
| SCHEMBL4965465 | 0.88 | PDE10A (0.57) | PDGFRBPDGFRAPDE10AHTR1AADRA1D | |
| SCHEMBL4965715 | 0.87 | PDGFRA (0.60) | PDGFRBPDGFRAPDE10AKITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101242838-A | Synergistic modulation of FLT3 kinase using aminoquinoline and aminoquinazoline kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1899319-A2 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1893206-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135649-A2 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135636-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, CDC42BPG, PRKCQ | PDGFRB 284/4885PDGFRA 460/4885PDE10A 4119/4885 |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, BMX, ABL1 | PDGFRB 51/4885PDGFRA 74/4885PDE10A 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.